Adeno-associated virus-mediated cancer gene therapy: Current status

Luo, Jingfeng; Luo, Yuxuan; Sun, Jihong; Zhou, Yurong; Zhang, Yajing; Yang, Xiaoming

doi:10.1016/j.canlet.2014.10.045

Cited by 66 publications

(58 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adenovirus can reach its highest level of transgene expression in a very short time, and the gene expression level declines with time. A lot of data have been accumulated, with non-replicating adenoviral vectors suggesting a reasonable safety profile in humans [21,22]. However, the infectivity of adenovirus is dependent on coxsackieadenovirus receptors.…”

Section: Discussionmentioning

confidence: 98%

Antitumor effect and underlying mechanism of RGD-modified adenovirus mediated IL-24 expression on myeloid leukemia cells

Xia²,

et al. 2015

International Immunopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Antitumor effect and underlying mechanism of RGD-modified adenovirus mediated IL-24 expression on myeloid leukemia cells

Xia²,

et al. 2015

International Immunopharmacology

View full text Add to dashboard Cite

“…However, the transfection was not stable. 3 Similarly, the application of liposomes was restricted by its potential genetic toxicity and low expression efficiency. Most importantly, the obstruction itself did not cause injury to the liver.…”

Section: Discussionmentioning

confidence: 99%

“…More than 2900 clinical trials of gene therapy have been carried out to date. 3 The gene vehicles currently in use include viral and non-viral vectors, such as adeno-associated virus and liposomal complexes. 2 Unlike conventional chemical drugs, nucleic acids are easily degraded in biological systems and have difficulty reaching the intracellular target.…”

Section: Introductionmentioning

confidence: 99%

Liver gene transfection by retrograde intrabiliary infusion facilitated by temporary biliary obstruction

Dai

Wang

Zhao

et al. 2020

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background:The hepatobiliary tract may be a valuable administration site for gene delivery. We demonstrated the role of temporary biliary obstruction for gene transfection by retrograde intrabiliary infusion. Methods:Male Sprague-Dawley rats received intrabiliary infusion of luciferase plasmid via an artificial common bile duct, with temporary biliary obstruction for 0 minutes (NO group), 30 minutes (30 min group) and 24 hours (24 h group), respectively (n = 4 for each group). Gene expression levels were evaluated by luciferase bioluminescence on postoperative days (POD) 1, 2 and 7. Serum and livers were collected on POD 1 and 14 for liver biochemistry, hematoxylin and eosin staining, and immunohistochemistry.Results: On POD 1, luciferase chemoluminescence was significantly higher in the 24 h group than in the NO group (p = 0.002) and the 30 min group (p = 0.002). However, it decreased rapidly after reversal of the obstruction in the 24 h group (POD 1 versus POD 2, p = 0.002; POD 1 versus POD 7, p = 0.002). Liver biochemistry was changed on POD 1, but no significant differences were detected after 14 days of recovery (p > 0.05). Similar histological changes were found in the three groups, with no unwanted proliferation of biliary epithelial cells. The obstruction did not cause serious liver damage.Conclusions: Temporary biliary obstruction for 24 hours facilitated the safe, feasible and effective transfection of plasmid DNA into the liver via the hepatobiliary tract. In the future, endoscopic retrograde cholangiopancreatography and its dilation balloon could be used to create biliary obstruction and allow the direct gene delivery into the liver. More research is necessary for achieving stable gene expression, as well as in terms of weighing its benefits against potential complications. K E Y W O R D Sartificial common bile duct, gene therapy, hepatobiliary tract, retrograde biliary infusion, temporary biliary obstruction Dai and Wang contributed equally to this work.

show abstract

“…(b) Adeno-Associated viruses (AAV) are small single-stranded (ss) DNA viruses which offer several advantages such as wide host range, low immune response (due to lack of pathogenicity) and long-term expression [77]. Recently several AAV-mediated genes have been developed to treat cancers such as prostate cancer, glioblastoma, cervical and breast cancer, nasopharyngeal carcinoma and lung carcinoma [78–81].…”

Section: Intracellular Targeted Drug Deliverymentioning

confidence: 99%

Novel delivery approaches for cancer therapeutics

Mitra

Agrahari

Mandal

et al. 2015

Journal of Controlled Release

130

View full text Add to dashboard Cite

Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery. Chemical and physical treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells. Furthermore, these approaches are often combined to enhance therapeutic indices. It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth. In addition, these treatment modalities are associated with severe side effects and high toxicity which in turn lead to low quality of life. This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis. Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies. In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment. These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects. Lowering, multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.

show abstract

Adeno-associated virus-mediated cancer gene therapy: Current status

Cited by 66 publications

References 121 publications

Antitumor effect and underlying mechanism of RGD-modified adenovirus mediated IL-24 expression on myeloid leukemia cells

Antitumor effect and underlying mechanism of RGD-modified adenovirus mediated IL-24 expression on myeloid leukemia cells

Liver gene transfection by retrograde intrabiliary infusion facilitated by temporary biliary obstruction

Novel delivery approaches for cancer therapeutics

Contact Info

Product

Resources

About